Cialis (tadalafil): a new treatment for erectile dysfunction.

Abstract

Oral phosphodiesterase inhibitors have become the mainstay of treatment for erectile dysfunction. A novel and potent phosphodiesterase inhibitor, tadalafil, known as Cialis, has been introduced in the UK as an alternative to the other currently available phosphodiesterase inhibitors for the treatment of erectile dysfunction.

• Authors: S Minhas, J S Kalsi, D J Ralph
• Journal: Hospital medicine (London, England : 1998) (Hosp Med) Vol. 64 Issue 10 Pg. 589-92 (Oct 2003) ISSN: 1462-3935 [Print] England
• PMID: 14584238 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Carbolines
• Phosphodiesterase Inhibitors
• Tadalafil

Topics

• Carbolines (administration & dosage, adverse effects, pharmacokinetics)
• Clinical Trials, Phase III as Topic
• Erectile Dysfunction (drug therapy)
• Humans
• Male
• Multicenter Studies as Topic
• Penile Erection (drug effects, physiology)
• Phosphodiesterase Inhibitors (administration & dosage, adverse effects, pharmacokinetics)
• Tadalafil